Solnatide | CAS#259206-53-6 | synthetic peptide

MedKoo Cat#: 592901 | Name: Solnatide

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Solnatide is a synthetic peptide derived from the lectin-like domain of tumor necrosis factor-alpha (TNF-α) and has been investigated for its ability to enhance alveolar fluid clearance (AFC) in acute respiratory distress syndrome (ARDS) and pulmonary edema. It primarily activates the epithelial sodium channel (ENaC), promoting sodium and fluid resorption in alveolar epithelial cells. Studies have demonstrated that Solnatide increases AFC in animal models of lung injury, improves lung compliance, and reduces pulmonary edema. In vitro, it enhances ENaC-mediated sodium uptake in human alveolar epithelial cells with an EC₅₀ in the nanomolar range.

Chemical Structure

Solnatide

CAS#259206-53-6

Theoretical Analysis

MedKoo Cat#: 592901

Name: Solnatide

CAS#: 259206-53-6

Chemical Formula: C82H119N23O27S2

Exact Mass: 1921.8087

Molecular Weight: 1923.11

Elemental Analysis: C, 51.21; H, 6.24; N, 16.75; O, 22.46; S, 3.33

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Solnatide

IUPAC/Chemical Name

L-Cysteine, L-cysteinylglycyl-L-glutaminyl-L-arginyl-L-alpha-glutamyl-L-threonyl-L-prolyl-L-alpha-glutamylglycyl-L-alanyl-L-alpha-glutamyl-L-alanyl-L-lysyl-L-prolyl-L-tryptophyl-L-tyrosyl-, cyclic (1->17)-disulfide

InChi Key

LKVFMOMQYXIFRK-KSVAIKAXSA-N

InChi Code

1S/C82H119N23O27S2/c1-40-67(117)95-52(23-27-64(113)114)71(121)93-41(2)68(118)99-54(13-6-7-29-83)79(129)104-31-9-15-58(104)78(128)101-56(34-44-35-89-48-12-5-4-11-46(44)48)76(126)100-55(33-43-17-19-45(107)20-18-43)75(125)102-57(81(131)132)39-134-133-38-47(84)69(119)90-37-62(110)94-51(21-25-60(85)108)73(123)96-49(14-8-30-88-82(86)87)72(122)97-53(24-28-65(115)116)74(124)103-66(42(3)106)80(130)105-32-10-16-59(105)77(127)98-50(22-26-63(111)112)70(120)91-36-61(109)92-40/h4-5,11-12,17-20,35,40-42,47,49-59,66,89,106-107H,6-10,13-16,21-34,36-39,83-84H2,1-3H3,(H2,85,108)(H,90,119)(H,91,120)(H,92,109)(H,93,121)(H,94,110)(H,95,117)(H,96,123)(H,97,122)(H,98,127)(H,99,118)(H,100,126)(H,101,128)(H,102,125)(H,103,124)(H,111,112)(H,113,114)(H,115,116)(H,131,132)(H4,86,87,88)/t40-,41-,42+,47-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,66-/m0/s1

SMILES Code

C[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@H]2C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)NCC(=O)N1)CCC(=O)O)[C@@H](C)O)CCC(=O)O)CCCNC(=N)N)CCC(=O)N)N)C(=O)O)Cc4ccc(cc4)O)Cc5c[nH]c6c5cccc6)CCCCN)C)CCC(=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 1,923.11 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Shabbir W, Tzotzos S, Bedak M, Aufy M, Willam A, Kraihammer M, Holzner A, Czikora I, Scherbaum-Hazemi P, Fischer H, Pietschmann H, Fischer B, Lucas R, Lemmens-Gruber R. Glycosylation-dependent activation of epithelial sodium channel by solnatide. Biochem Pharmacol. 2015 Dec 15;98(4):740-53. doi: 10.1016/j.bcp.2015.08.003. Epub 2015 Aug 5. PubMed PMID: 26254591. 2: Lucas R, Yue Q, Alli A, Duke BJ, Al-Khalili O, Thai TL, Hamacher J, Sridhar S, Lebedyeva I, Su H, Tzotzos S, Fischer B, Gameiro AF, Loose M, Chakraborty T, Shabbir W, Aufy M, Lemmens-Gruber R, Eaton DC, Czikora I. The Lectin-like Domain of TNF Increases ENaC Open Probability through a Novel Site at the Interface between the Second Transmembrane and C-terminal Domains of the α-Subunit. J Biol Chem. 2016 Nov 4;291(45):23440-23451. Epub 2016 Sep 19. PubMed PMID: 27645999; PubMed Central PMCID: PMC5095400. 3: Willam A, Aufy M, Tzotzos S, El-Malazi D, Poser F, Wagner A, Unterköfler B, Gurmani D, Martan D, Iqbal SM, Fischer B, Fischer H, Pietschmann H, Czikora I, Lucas R, Lemmens-Gruber R, Shabbir W. TNF Lectin-Like Domain Restores Epithelial Sodium Channel Function in Frameshift Mutants Associated with Pseudohypoaldosteronism Type 1B. Front Immunol. 2017 May 29;8:601. doi: 10.3389/fimmu.2017.00601. eCollection 2017. PubMed PMID: 28611771; PubMed Central PMCID: PMC5447021. 4: van den Berg E, Bem RA, Bos AP, Lutter R, van Woensel JB. The effect of TIP on pneumovirus-induced pulmonary edema in mice. PLoS One. 2014 Jul 21;9(7):e102749. doi: 10.1371/journal.pone.0102749. eCollection 2014. PubMed PMID: 25047452; PubMed Central PMCID: PMC4105480. 5: Czikora I, Alli A, Bao HF, Kaftan D, Sridhar S, Apell HJ, Gorshkov B, White R, Zimmermann A, Wendel A, Pauly-Evers M, Hamacher J, Garcia-Gabay I, Fischer B, Verin A, Bagi Z, Pittet JF, Shabbir W, Lemmens-Gruber R, Chakraborty T, Lazrak A, Matthay MA, Eaton DC, Lucas R. A novel tumor necrosis factor-mediated mechanism of direct epithelial sodium channel activation. Am J Respir Crit Care Med. 2014 Sep 1;190(5):522-32. doi: 10.1164/rccm.201405-0833OC. PubMed PMID: 25029038; PubMed Central PMCID: PMC4214088. 6: Schwameis R, Eder S, Pietschmann H, Fischer B, Mascher H, Tzotzos S, Fischer H, Lucas R, Zeitlinger M, Hermann R. A FIM study to assess safety and exposure of inhaled single doses of AP301-A specific ENaC channel activator for the treatment of acute lung injury. J Clin Pharmacol. 2014 Mar;54(3):341-50. doi: 10.1002/jcph.203. PubMed PMID: 24515273; PubMed Central PMCID: PMC4160070. 7: Zhou Q, Wang D, Liu Y, Yang X, Lucas R, Fischer B. Solnatide Demonstrates Profound Therapeutic Activity in a Rat Model of Pulmonary Edema Induced by Acute Hypobaric Hypoxia and Exercise. Chest. 2017 Mar;151(3):658-667. doi: 10.1016/j.chest.2016.10.030. Epub 2016 Nov 1. PubMed PMID: 27815150. 8: Shabbir W, Scherbaum-Hazemi P, Tzotzos S, Fischer B, Fischer H, Pietschmann H, Lucas R, Lemmens-Gruber R. Mechanism of action of novel lung edema therapeutic AP301 by activation of the epithelial sodium channel. Mol Pharmacol. 2013 Dec;84(6):899-910. doi: 10.1124/mol.113.089409. Epub 2013 Sep 27. PubMed PMID: 24077967; PubMed Central PMCID: PMC3834145. 9: Tzotzos S, Fischer B, Fischer H, Pietschmann H, Lucas R, Dupré G, Lemmens-Gruber R, Hazemi P, Prymaka V, Shabbir W. AP301, a synthetic peptide mimicking the lectin-like domain of TNF, enhances amiloride-sensitive Na(+) current in primary dog, pig and rat alveolar type II cells. Pulm Pharmacol Ther. 2013 Jun;26(3):356-63. doi: 10.1016/j.pupt.2012.12.011. Epub 2013 Jan 9. PubMed PMID: 23313096; PubMed Central PMCID: PMC3646188. 10: Willam A, Aufy M, Tzotzos S, Evanzin H, Chytracek S, Geppert S, Fischer B, Fischer H, Pietschmann H, Czikora I, Lucas R, Lemmens-Gruber R, Shabbir W. Restoration of Epithelial Sodium Channel Function by Synthetic Peptides in Pseudohypoaldosteronism Type 1B Mutants. Front Pharmacol. 2017 Feb 24;8:85. doi: 10.3389/fphar.2017.00085. eCollection 2017. PubMed PMID: 28286482; PubMed Central PMCID: PMC5323398. 11: Aigner C, Slama A, Barta M, Mitterbauer A, Lang G, Taghavi S, Matilla J, Ullrich R, Krenn K, Jaksch P, Markstaller K, Klepetko W. Treatment of primary graft dysfunction after lung transplantation with orally inhaled AP301: A prospective, randomized pilot study. J Heart Lung Transplant. 2017 Sep 30. pii: S1053-2498(17)32036-3. doi: 10.1016/j.healun.2017.09.021. [Epub ahead of print] PubMed PMID: 29055604.